This renewal application requests funding for the 25th through 29th years of the NCI Cancer Center Support Grant of the City of Hope Comprehensive Cancer Center. The Center now has five research programs: one basic research Program (Cancer Biology, CB);three clinical/translational research Programs (Developmental Cancer Therapeutics, DCT;Cancer Immunotherapeutics, Cl;Hematologic Malignancies, HM);and one population research program (Cancer Control and Population Sciences, CCPS). Twelve shared resources support the scientific activities of the members, including two new cores (Small Animal Imaging;Clinical Immunobiology Correlative Studies Laboratory). Three developing cores are proposed (High Throughput Screening;Synthetic &Biopolymer Chemistry;Survey Research). Membership has grown by 45% in the preceding program period with the recruitment of 37 new Full Members, including several key senior leaders (Richard Jove, PhD, Deputy Director;R. Figlin, MD, Associate Director [AD] for Clinical Research). Other key leadership positions have also been filled through internal appointments (Smita Bhatia, MD, MPH, AD for Population Research;Joyce Niland, PhD, AD for Information Sciences;and Yun Yen, MD, PhD, AD for Translational Research). As a result of our program restructuring, recruitment and infrastructure development, we now believe we have a Center where our five Programs represent a continuum in which basic and translational studies in the basic science Program, CB, and one clinical Program, DCT, can be linked to Phase I and II clinical protocols in all three clinical programs (DCT, Cl, HM) and follow-up studies in survivorship and symptom management in the population sciences program (CCPS). All these activities are made possible by a Center and Institutional infrastructure that supports basic and translational research in biological and, now, small molecule approaches to cancer in an extraordinarily collaborative fashion. Such interaction has resulted in the Center's first SPORE, in lymphoma;a recent W.M. Keck Foundation award;and the renewal of eight large, multi-investigator awards. During the next funding period, we will build on these achievements so that the City of Hope Comprehensive Cancer Center takes the next step in its evolution: translating more laboratory discoveries into innovative clinical trials and developing disease-based research programs. The 82 Full Members and 90 Associate Members of the Center Programs have published 1001 articles, book chapters, etc., since the last competitive grant review. Of these, 28% are intraprogrammatic and 22% are interprogrammatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-29
Application #
8209208
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-08-01
Project End
2013-04-24
Budget Start
2011-12-01
Budget End
2013-04-24
Support Year
29
Fiscal Year
2012
Total Cost
$2,225,352
Indirect Cost
$884,778
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Zhang, Keqiang; Wang, Jinhui; Yang, Lu et al. (2018) Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer. Mol Cancer 17:153
Liu, Liang; Yang, Lin; Yan, Wei et al. (2018) Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clin Cancer Res 24:2370-2382
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528
Moreira, Dayson; Adamus, Tomasz; Zhao, Xingli et al. (2018) STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin Cancer Res 24:5948-5962
Choi, Audrey H; O'Leary, Michael P; Chaurasiya, Shyambabu et al. (2018) Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer. Surgery 163:336-342
Golfetto, Ottavia; Wakefield, Devin L; Cacao, Eliedonna E et al. (2018) A Platform To Enhance Quantitative Single Molecule Localization Microscopy. J Am Chem Soc 140:12785-12797
Wolfson, Julie A; Richman, Joshua S; Sun, Can-Lan et al. (2018) Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment. Cancer Epidemiol Biomarkers Prev 27:1133-1141
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 1396 publications